ALLMedicine™ Lymphangioleiomyomatosis Center

Jun 24th, 2022 - Disorders of lymphatic function are associated with multiple presentations, the most common of which is lymphedema, a chronic swelling of the extremities, due to impaired lymphatic drainage. It can cause disability and a predisposition to infectio...

Jun 24th, 2022 - We have reported that approximately one third of patients with lymphangioleiomyomatosis (LAM) who have airflow obstruction respond to bronchodilators such as albuterol, a Beta2-adenergic receptor agonist, with an increase in forced expiratory flow...

Jun 24th, 2022 - Sirolimus (rapamycin), which acts as a targeted inhibitor of the protein mechanistic target of rapamycin (mTOR), has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). It stabilizes lung function, resolves chylous effusion...

Jun 24th, 2022 - Individuals with pulmonary lymphangioleiomyomatosis develop severe destructive lung disease. Most of them are females of childbearing age. Currently, there is no proven effective therapy and the prognosis is variable. This study is designed to (a)...

Jun 19th, 2022 - Lymphangioleiomyomatosis (LAM) is a rare multisystemic disorder with various clinical manifestations. Despite the recognition of several prognostic factors, the long-term clinical course and prognosis of patients with LAM in the era of sirolimus t...

May 11th, 2010 - Lymphangioleiomyomatosis (LAM) is a rare lung disease which predominantly affects young women. LAM is associated with much morbidity and can lead to respiratory failure and death unless lung transplantation is performed. There are no randomised tr...

Jan 2nd, 2010 - European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.|2010|Johnson SR,Cordier JF,Lazor R,Cottin V,Costabel U,|complications,diagnosis,therapy,

Jun 24th, 2022 - Disorders of lymphatic function are associated with multiple presentations, the most common of which is lymphedema, a chronic swelling of the extremities, due to impaired lymphatic drainage. It can cause disability and a predisposition to infectio...

Jun 24th, 2022 - We have reported that approximately one third of patients with lymphangioleiomyomatosis (LAM) who have airflow obstruction respond to bronchodilators such as albuterol, a Beta2-adenergic receptor agonist, with an increase in forced expiratory flow...

Jun 24th, 2022 - Sirolimus (rapamycin), which acts as a targeted inhibitor of the protein mechanistic target of rapamycin (mTOR), has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). It stabilizes lung function, resolves chylous effusion...

Jun 24th, 2022 - Individuals with pulmonary lymphangioleiomyomatosis develop severe destructive lung disease. Most of them are females of childbearing age. Currently, there is no proven effective therapy and the prognosis is variable. This study is designed to (a)...

May 18th, 2022 - This is a physiopathological case-control, non-interventional, monocentric study of adult patients with lymphangioleiomyomatosis. The controls are patients followed in neurology at the CHU of Tours for a tuberous sclerosis complex without lymphang...

Mar 29th, 2019 - Cystic and calcified PEComa of the ligamentum teres PEComas are tumors derived from epithelioid perivascular cells that typically coexpress smooth muscle and melanocytic markers. The family of PEComas includes angiomyolipoma, clear cell “sugar” tu.

Mar 29th, 2019 - Cystic and calcified PEComa of the ligamentum teres PEComas are tumors derived from epithelioid perivascular cells that typically coexpress smooth muscle and melanocytic markers. The family of PEComas includes angiomyolipoma, clear cell “sugar” tu.

Mar 29th, 2019 - Cystic and calcified PEComa of the ligamentum teres PEComas are tumors derived from epithelioid perivascular cells that typically coexpress smooth muscle and melanocytic markers. The family of PEComas includes angiomyolipoma, clear cell “sugar” tu.

Feb 6th, 2018 - Giants In Chest Medicine Professor Nan-shan Zhong, MD. By Wei-jie Guan.

Mar 28th, 2017 - In 2012, new criteria for the diagnosis of TSC were published by the International Tuberous Sclerosis Complex Consensus Conference.[13] They include the following 11 major and six minor features. The major features are as follows: Hypomelanotic ma...